Texas
LATEST FROM BIOSPACE
Mr. Hartman overviewed the Company’s Anti-Cancer R&D program and discussed his intent to find a licensee for the technology or investment partner to complete the development of this very promising anti-cancer antibody drug.
Baker and ex-ArthroCare CFO Michael Gluk were convicted in June 2014 on charges that they ran a scheme to generate false revenue numbers
For most biopharma sponsors, the crux of their challenge is how to identify an adequate number of evaluable patients to sufficiently power their late phase clinical research.
Corinnova’s CEO says the company has developed a device called EpicHeart to tackle heart failure.
What are the risks and benefits of taking such a step? And what factors are important to consider before doing so?
Biotech has been on fire this year, with the iShare Nasdaq Biotechnology index more than doubling the gains of the S&P 500 year-to-date.
PRESS RELEASES